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Abstract: Over the past years, there is a growing number of newly diagnosed pediatric patients with 
Crohn’s disease (CD). Severe course of CD oft en requires biological treatment with Infl iximab (IFX). 
Loss of response to biological treatment is a major problem. Mean platelet volume (MPV) was reported 
as a good marker of sustained response to IFX therapy in adults. Th is study is to determine whether MPV 
measured prior to IFX therapy and aft er its third dose can be used as a predictive marker of sustained 
response to biological therapy in children with severe course of CD. 43 pediatric patients with CD who un-
derwent IFX therapy were enrolled into this study. Th e clinical response was evaluated aft er the third dose 
and aft er one year of IFX treatment (sustained response). Th e MPV values at baseline and week 14 were 
compared to the patients with good response to IFX to those with loss of the response. During 52-week 
IFX therapy, 2 out of 43 patients enrolled in the study did not achieve primary response aft er the third 
dose, another 18 children lost their response to the above therapy aft er one year. Th ere was no signifi cant 
association between baseline and 14th week values of MPV between patients with the sustained response 
to those with loss of response. In opposite to adult patients, MPV cannot be regarded as predictive factor 
of sustained response to IFX treatment in pediatric patients. 
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Introduction
Inflammatory bowel disease (IBD) is a  chronic inflammatory process of the 
gastrointestinal tract, characterized by periods of exacerbations and remissions, and 
leading to multiple health complications. Crohn’s disease (CD) is a  predominant 
IBD in pediatric patients. Th e pathogenesis of CD is complex, and still not entirely 
understood. Over the last few years, a growing number of newly diagnosed pediatric 
patients with extensive CD can be observed [1]. Th e recommended treatment in the 
early onset and severe course of the disease requires anti-TNF-α antibodies therapy 
with Infl iximab (IFX) or Adalimumab (ADA) to support long-term remission and 
to prevent chronic complications. Loss of response to IFX in CD is a  major clinical 
problem. It aff ects 23–46% of adult patients aft er 12-month therapy [2]. Such 
inhibition process is also observed in children, and oft en precludes further use of 
IFX [3]. In the latest research, it is proposed that the CD patients develop antibodies 
blocking anti-TNF-α agents causing loss of treatment response [3, 4]. Th ere is also 
suspected role of other factors involved in development of CD, especially those 
associated with rise of the pro-infl ammatory cytokines, such as IL-12, IL-17, IL-23 
[5, 6]. Th ere are several blood biomarkers used to reveal, monitor and evaluate both 
exacerbation of CD and response to IFX, which include erythrocyte sedimentation 
rate (ESR), C-reactive protein (CRP), white blood count (WBC), platelet count (PLT) 
and albumin level [7]. Recent studies suggest that platelets can have important role 
in the pathogenesis of CD [8]. Th ere are also reports which list mean platelet volume 
(MPV) as a good predictor of a sustained response to infl iximab therapy in adults [9]. 
Th is study was designed to assess whether MPV can also be used as a valid marker of 
a sustained response to anti-TNF-α therapy in pediatric patients.
Materials and methods
Patients
Th is report presents a  retrospective pilot study. A population of 62 pediatric patients 
diagnosed with severe CD was treated with anti-TNF-α agents in Department of 
Pediatrics Gastroenterology and Nutrition, Jagiellonian University Medical College in 
Krakow, Poland, between January 2012 and March 2016. Th e group of 43 children, 
which included 23 girls (54%) and 20 boys (46%) with mean age 15.0 years [10.5; 16.0] 
met our inclusion criteria, and were enrolled into the study (Figure  1). Th e control 
group consisted of 43 age and sex matched children hospitalized at our Clinic, 
diagnosed with dyspepsia, irritable bowel syndrome (IBS) or small intestinal bacterial 
overgrowth (SIBO). Th e inclusion criteria for CD pediatric patients were: Caucasian, 
age between 2–17 years old, diagnosed with severe CD (Pediatric Crohn’s Disease 
Activity Index, PCDAI >50 points), qualifi ed for infl iximab therapy, complete medical 
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documentation. Th e exclusion criteria were: isolated perianal disease, age under 
2 years old and over 17 years old, pregnancy, use of anti-infl ammatory drugs (except 
azathioprine, 6-mercaptopurine, steroids), concomitant conditions such as: atopic 
dermatitis, diabetes, pulmonary or kidney disease, leukemia. Th e complete physical 
examination, laboratory tests and endoscopic examination (gastrodudodenoscopy and 
ileocolonoscopy) were performed in all the patients as the baseline of the study. CD 
diagnosis was made based on the clinical, endoscopic, radiological and pathological 
evaluation according to European Society for Pediatric Gastroenterology, Hepatology 
and Nutrition (ESPGHAN) revised PORTO criteria for the diagnosis of infl ammatory 
bowel disease in children and adolescents [10]. Th e activity of disease was checked 
at designated time points before and during therapy according to Pediatric Crohn’s 
Disease Activity Index (PCDAI) [11]. PCDAI is a  complex scoring system covering 
clinical symptoms (severity of abdominal pain, number and consistency of stools, 
patient general activity), laboratory tests (ESR, albumin, hematocrit values), growth 
delay, perianal changes and extra intestinal manifestation of CD. Th e criteria to 
initiate biological therapy were PCDAI score over 50 points, lack of eff ect of the 
conventional treatment (mesalazine, azathioprine, corticosteroids, clinical nutrition 
therapy). All the patients enrolled in this biological treatment received an induction 
treatment: 5 mg/kg IFX infusion at baseline and next 5 mg/kg at the 2nd and 6th week. 
Aft er the third dose of IFX (14th week), the primary response was evaluated and the 
patients underwent second endoscopic examination, followed by selection for further 
biological treatment. A good response to therapy was defi ned as an improvement 
of endoscopic changes and reduction in PCDAI score by ≥12.5 points and clinical 
remission by PCDAI total score ≤30 points. Loss of the response during therapy was 
Fig. 1. Study design: A total of 86 subjects were enrolled into this study. 43 healthy controls were 
compared with CD pediatric patients (Infl ammatory markers: CRP, WBC, ESR, PLT, MPV). CD patients 
were treated during 52 week therapy with anti-TNF-α agent Infl iximab. Th an laboratory parameters of 
patients who lost response were compared to the results of patients with sustained response.
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defi ned as one of following: exacerbation of disease with PCDAI score ≥30 points 
during at least 2 subsequent visits, CD-related laparotomy, crossover from the 
scheduled therapy (every 8 weeks) to episodic treatment. Administration of IFX was 
performed every 8 weeks for the next 38 weeks. Aft er one year of therapy, the patients 
underwent third endoscopic evaluation.
Laboratory parameters
Blood samples for laboratory analysis were taken twice, fi rst — during qualifi cation 
for biological treatment procedure (before the first dose of IFX), and then 
during evaluation of effi  cacy of induction treatment (aft er 14th week). Blood was 
automatically analyzed within 2 hours aft er its collection. Th e samples of 2 ml of 
ethylenediaminetetraacetic acid (EDTA)-anticoagulated venous blood were used to 
analyze platelet parameters (MPV and PDW), and another 2 ml of venous blood was 
placed in the serum tubes to assess biochemistry and CRP level. Th e reference range 
for MPV in children is 6.5–10 fl , and for CRP <5 mg/L.
Statistical analysis
Statistical analysis was performed using Statistica soft ware, version 12. Data were 
presented as number of patients (percentage of the group) for categories, and median 
[lower; upper quartile] for qualitative variables. Chi-squared test, t-test and Mann–
Whitney test were used to study diff erences between groups, according to distribution 
(as tested with Shapiro–Wilk test). Correlations were assessed with Pearson or 
Spearman coeffi  cient. Th e results were considered statistically signifi cant when p <0.05. 
Ethical considerations
Th e study was approved by the Bioethics Committee of Jagiellonian University, 
Kraków. (No:122.6120.52.2015)
Results
Diff erences between pediatric patients with CD and healthy controls
Demographic parameters of the pediatric CD patients and the control group are 
presented in Table 1. Th e two groups were matched according to their gender and 
age, however, body mass index (BMI) in the CD children was signifi cantly lower 
compared to controls. Th e children with CD demonstrated signifi cantly higher platelet 
counts, and lower platelet parameters such as platelet distribution width, and medium 
platelet volume than in the control group (Table 2).
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Table 1. Demographic features of pediatric CD patients and control group. BMI-body mass index.
Pediatric CD patients n = 43 Control group n = 43 p-value
Gender male (46.5%) female (53.5%) male (46.5%) female (53.5%) 1.000
Age 15.0 [10.5; 16.0] 14.0 [10.5; 16.2] 0.798
BMI 16.4 [14.5; 18.0] 18.2 [15.9; 21.0] 0.009
Table 2. Comparison of platelet counts (PLT), platelet distribution width (PDW) and mean platelet 
volume (MPV) between CD patients (at baseline) and control group.
Pediatric CD patients n = 43 Control group n = 43 p-value
PLT ths/ul 483.0 [346.5; 532.5] 247.0 [219.0; 281.5] <0.001
PDW fl . 10.2 [9.5; 11.1] 12.1 [11.1; 13.5] <0.001
MPV fl . 9.4 [8.8; 9.9] 10.4 [9.9; 11.1] <0.001
Table 3 demonstrates that the main infl ammatory markers: erythrocyte sedimen-
tation rate (ESR), C-reactive protein (CRP), white blood count (WBC) were also 
signifi cantly higher in CD patients. Hemoglobin, hematocrit, red blood count levels 
were lower in the CD pediatric patients in comparison to control group (Table 4).
Table 3. Diff erences between CD patients and control group — infl ammatory markers: erythrocyte 
sedimentation rate (ESR), C-reactive protein (CRP), white blood count (WBC).
Pediatric CD patients Control group p-value
ESR mm/h 24.0 [15.0; 44.0] 5.0 [3.0; 7.0] <0.001 
CRP mg/L 15.7 [6.1; 40.5] 5.0 [5.0; 5.0] <0.001 
WBC ths/ul 9.6 [6.7; 12.4] 5.9 [5.0; 7.2] <0.001 
Table 4. Hematocrit (HCT), Hemoglobin (HGB) and red blood count (RBC) in CD patients and control 
group.
Pediatric CD patients Control group p-value
RBC mln/ul 4.3 [4.0; 4.8] 4.8 [4.6; 5.0] 0.002
HGB g/dl 12.0 [10.8; 12.9] 13.5 [12.9; 14.3] <0.001
HCT % 38.1 [33.7; 40.8] 40.6 [39.2; 42.2] <0.001
Correlations
We did not observe any correlations between MPV and BMI or ESR, or WBC value, 
however, we identifi ed a negative correlation between MPV and CRP (Table 5).
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Table 5. Correlations at baseline between MPV (mean platelet volume) and BMI (body mass index) and 
infl ammatory markers in CD pediatric patients (n = 43). WBC (white blood count); ESR (erythrocyte 
sedimentation rate); CRP (C-reactive protein).
r-value p-value
BMI  0.08 0.601
WBC ths/ul –0.13 0.406
ESR mm/h –0.13 0.395
CRP mg/L –0.39 0.010
Comparison of pediatric CD patients 
with sustained response to IFX (responders) 
to the ones who lost response to IFX during 52-week therapy (non-responders)
During a  yearlong therapy, 20 out of 43 patients (7 boys, 13 girls) gradually lost 
their IFX response, while the other 23 patients demonstrated sustained response to 
biological treatment. We compared the results from the group that lost response to 
IFX with those children, who maintained their response. Th e signifi cant diff erences 
were observed. Th e activity of the disease measured by PCDAI in responders group 
was signifi cantly lower than PCDAI in the non-responders group (0.0 [0.0; 5.0] vs. 8.8 
[4.4; 15.6]; p <0.001). Th e decline of PCDAI, analyzed as delta PCDAI measured before 
the fi rst dose and aft er the third dose was signifi cantly lower in the non-responders in 
comparison to the responders (–45.0 [–52.5; –36.2] vs. –52.5 [–52.5; –50.0]; p = 0,007). 
Th ere were no signifi cant diff erences regarding change in PLT (Δ PLT) or MPV levels 
(Δ MPV) between the two groups. Out of analyzed infl ammatory markers, only ESR 
levels were signifi cantly higher in the non-responders than in the responders group 
(20.5 [9.8; 29.2] vs. 7.0 [4.0; 11.5]; p = 0.001). It was interesting to fi nd out that the 
children with sustained response to IFX had signifi cantly higher levels of hemoglobin 
compared to the patients who lost response to IFX (12.9 [12.2; 13.7] vs. 11.2 [10.9; 
13.0]; p = 0.009) (Table 6).
Table 6. Comparison of baseline mean platelet volume (MPV), platelet count (PLT) and Δ MPV, Δ PLT 
(during 14 week therapy) between responders and non-responders to IFX therapy.
Non-responders n = 20 Responders n = 23 p-value
PLT ths/ul 372.0 [314.5; 431.2] 328.0 [266.0; 410.0] 0.073
MPV fl 9.8 [9.4; 10.8] 9.6 [9.4; 10.3] 0.583
ΔPLT ths/ul –85.5 [–179.5; –60.5] –65.0 [–194.5; –33.0] 0.884
ΔMPV fl 0.4 [0.1; 0.7] 0.6 [0.2; 1.1] 0.414
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Discussion
Despite signifi cant progress in CD therapy, IFX (and its biosimilars) therapy remains 
the most important treatment for severe pediatric CD patients. IFX is a  chimeric 
(human-mice) monoclonal antibody biologic drug that works against tumor necrosis 
factor alpha (TNF-α) and is used to treat infl ammatory bowel diseases. It was fi rst 
approved to use in adult population in 1999. In May 2006, it was approved to use in 
severe course of CD in pediatric patients. Th e loss of response to IFX is attributed to 
production of anti-IFX antibodies by the recipient’s immune system [4].
Mean platelet volume is one of the platelet indices, automatically assessed, that 
adds no extra cost or eff ort to a  full blood count examination. MPV normal value 
in pediatric patients is estimated between 6.5–10 fl . Th is is a  constant parameter 
that does not change with age. It is assumed to be influenced by BMI [12], but 
we did not find this correlation significant in our research. Many studies show 
a possible association between MPV value and pediatric infl ammatory diseases such 
as rheumatoid arthritis, juvenile idiopathic arthritis, acute appendicitis and viral 
gastroenteritis [13–15]. It is also assumed that MPV can be used in diagnostic process 
of IBD patients and as a marker to predict treatment response to IFX in adults [16, 9]. 
It is hypothesized that larger platelets are cumulated in infl ammation sites, such as 
intestine walls in IBD; therefore, only small platelets with low MPV are circulating 
in the bloodstream and can be easily detected [16]. Th e other explanation of this 
phenomenon is that infl ammatory reaction mediated by pro-infl ammatory cytokines 
and acute phase reactants stimulates megakariocytopoiesis and increases production 
of small size platelets [8]. Th ere are also reports that IFX therapy can ameliorate the 
hypercoagulable state in adult patients with CD probably due to platelet changes [17].
In this study, we demonstrate that there is no signifi cant correlation between MPV 
value and BMI, or between MPV and infl ammatory markers, such as ESR or WBC in 
CD patients. However, we identify a negative correlation between MPV and CRP. In 
contrast to the earlier fi ndings in CD adult patients [9], this study does not confi rm 
MPV value as a signifi cant predictor of response to IFX in children with severe CD. 
Although MPV is not a  good predictive marker of the response to IFX therapy, it 
might still be used to diff erentiate between CD patients and healthy children. Loss 
of response in pediatric CD patients undergoing maintenance therapy with IFX is 
a  warring phenomenon, and we observed this pattern in our study. Th erefore, new 
markers for monitoring response to biological treatment are needed, and they can 
change existing approach to patients’ follow-up.
Implementation of appropriate treatment is crucial for the course of the disease. 
Th is study shows that patients with lower initial PCDAI, ESR, and higher hemoglobin 
level respond better to IFX therapy and can develop sustained response. It is an 
interesting observation that children with initially lower activity of the disease and 
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with higher concentration of hemoglobin respond better to this biological treatment. 
Th is outcome is in accordance with the latest study, which shows that early IFX 
induction treatment (“top-down” strategy) is more eff ective in pediatric CD patients 
than conventional therapy (“step-up” strategy) [18]. Such studies may result in new 
recommendations of earlier introduction of infl iximab in patients with moderate to 
severe CD.
Conclusion
We demonstrated that MPV cannot be used as a  valid predictive marker of the 
sustained response to IFX therapy, but it can help to diff erentiate healthy children 
from the children suff ering from CD. Additionally, it appears that the earlier 
administration of IFX in pediatric patients with lower activity of the disease (lower 
ESR and higher concentration of hemoglobin), more likely maintains their response 
to the biological anti-TNF-α therapy.
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